Health TrialsbyHealthPanel

¹⁹F (Perfluoropropane) MRI

ConditionHealthy Volunteers - Male and Female
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorAlexei Ouriadov

About this trial

Healthy volunteers aged 18 to 85 will undergo ¹⁹F (perfluoropropane) MRI to support the development of imaging sequences, reconstruction algorithms, and hardware necessary for acquiring high-spatial resolution lung images. The study will also evaluate signal-to-noise ratio, contrast-to-noise ratio, spatial resolution, scan duration, and pulmonary gas exchange measurements derived from ¹⁹F (perfluoropropane) MRI.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Patient understands study procedures and is willing to participate in the study as indicated by the patient's signature.

Provision of written, informed consent prior to any study specific procedures.

Males and females aged 18 to 85 years.

Participant must be able to perform a breath-hold for 16s.

Disqualifiers

Patient has an MR incompatible implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) (at the discretion of the MRI Technologist).

In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI or CT, such as severe claustrophobia.

Participants who are pregnant, breastfeeding or have a positive pregnancy test at initial screening visit.

Participant is unable to perform spirometry maneuvers.

Trial design

Design model

Single group

Treatments tested in this trial

  • 19F(perfluoropropane) MRI

    Device

    19F(perfluoropropane) MRI is an emerging technique for imaging lung ventilation using inhaled, inert fluorinated gas. In contrast to proton-based MRI imaging, perfluoropropane gas is used as a contrast agent to directly visualize the airways, and thus ventilation. In this study, we aim to develop and evaluate an inert fluorinated gas-based MRI (19F MRI) technique to enhance non-invasive imaging in healthy adults without a history of acute or chronic respiratory disease.

Treatment groups

200 Participants
are divided into 1 treatment group
Group A: ¹⁹F (perfluoropropane) MRIExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Image spatial resolution

The primary endpoints are to assess the necessary imaging sequences, reconstruction algorithms, and hardware to acquire high spatial resolution lung images from MRI. Image spatial resolution (mm) is the ability of the imaging system to distinguish small structures, expressed as the smallest detectable detail in millimeters. Higher spatial resolution (smaller values) allows finer anatomical detail to be visualized.

Time frame
5 years
2

Signal-to-noise ratio (SNR)

A quantitative measure of image quality that compares the level of the desired signal to the background noise in an MRI image. Higher SNR values indicate clearer images with less noise, allowing for better visualization of anatomical structures.

Time frame
5 years
3

Contrast-to-noise ratio (CNR)

A measure of how well different tissues or structures can be distinguished from each other in an image relative to background noise. Higher CNR indicates better contrast and improved visibility of anatomical differences.

Time frame
5 years
4

Scan duration (minutes)

The total time required to complete the imaging acquisition for the protocol, measured in minutes.

Time frame
5 years

Secondary outcomes

1

Ventilation Defect Percent (VDP) of the lung

VDP is a widely used noble gas MRI biomarkers that is calculated by normalizing ventilation defect volume to the thoracic cavity.

Time frame
5 years
2

Fractional Ventilation (r)

Fractional Ventilation (r) is a quantitative imaging biomarker representing the fraction of gas volume in a lung region that is replaced by fresh inhaled air during a single breath. It is calculated using gas magnetic resonance imaging (MRI), where dynamic imaging tracks the wash-in and wash-out of inhaled gases (e.g., 19F (perfluoropropane)) within lung voxels. Fractional ventilation provides a regional measure of pulmonary ventilation efficiency and heterogeneity.

Time frame
5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Alexei Ouriadov

Lead sponsor

Western University

Sponsor institution

St. Joseph's Health Care London

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: